mosunetuzumab + cyclophosphamide + doxorubicin + vincristine + prednisone

**mosunetuzumab + cyclophosphamide + doxorubicin + vincristine + prednisone** is a multi-agent combination therapy under clinical investigation for hematological cancers, particularly aggressive B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL). - **Mosunetuzumab** is a bispecific, T-cell-engaging monoclonal antibody that targets both CD20 (on B cells) and CD3 (on T cells), redirecting T cells to eliminate malignant B cells by inducing cytotoxicity. - **Cyclophosphamide, doxorubicin, vincristine, and prednisone** are classical chemotherapeutic agents commonly known as the CHOP regimen. Cyclophosphamide is an alkylating agent, doxorubicin is an anthracycline antibiotic causing DNA damage, vincristine disrupts microtubules, and prednisone is a glucocorticoid that modulates immune response and anti-inflammatory activity. This combination is designed to synergize targeted immunotherapy (mosunetuzumab) with established cytotoxic chemotherapy (CHOP), aiming to improve response rates and durability of remission in patients with relapsed or refractory or newly diagnosed aggressive lymphomas[1][3][5].